Finance

Lists
SABS:NASDAQ
SAB Biotherapeutics Inc
2,99 $
-1,64%
(-0,050) 1D
23 հոկ, 11:04:08 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
2,98 $
High
3,04 $
Low
2,94 $
Mkt. cap
272,05 մլն
Avg. vol.
727,08 հզր
Volume
473,66 հզր
52-wk high
5,15 $
52-wk low
2,44 $
EPS
-0,63 $
Beta
0,57
Shares outstanding
90,99 մլն
No. of employees
86
Open
2,98 $
High
3,04 $
Low
2,94 $
Mkt. cap
272,05 մլն
Avg. vol.
727,08 հզր
Volume
473,66 հզր
52-wk high
5,15 $
52-wk low
2,44 $
EPS
-0,63 $
Beta
0,57
Shares outstanding
90,99 մլն
No. of employees
86
News stories
From web sources and news partners
About SAB Biotherapeutics Inc
CEO-
Employees86
Founded2014
HeadquartersՄայամի Բիչ, Ֆլորիդա, Միացյալ Նահանգներ
Sector-
Websitesab.bio
Analyst ratings
Based on 3 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current 2,99 $
15,00 $ (+401,67%)
Average
12,67 $ (+323,75%)
Lowest
10,00 $ (+234,45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eliana Merle
Barclays
Buy
Maintained
13,00 $
+334,8%
08/07/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
10,00 $
+234,4%
08/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
15,00 $
+401,7%
08/07/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
16,00 $
+435,1%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
6,00 $
+100,7%
06/16/2026
Samantha Semenkow
Citi
Buy
Reiterated
11,00 $
+267,9%
06/15/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
14,00 $
+368,2%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
11,00 $
+267,9%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
15,00 $
+401,7%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
13,00 $
+334,8%
04/02/2026
Michael Yee
UBS
Buy
Maintained
7,00 $
+134,1%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
8,97 մլն
9,73 մլն
13,40 մլն
16,17 մլն
Cost of revenue
8,97 մլն
9,73 մլն
13,40 մլն
16,17 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,71 մլն
6,04 մլն
6,60 մլն
7,20 մլն
Operating expense
3,71 մլն
6,04 մլն
6,60 մլն
7,20 մլն
Total operating expenses
12,68 մլն
15,77 մլն
20,00 մլն
23,38 մլն
Operating income
-12,68 մլն
-15,77 մլն
-20,00 մլն
-23,38 մլն
Other non operating income
57,51 մլն
-1,73 մլն
144,40 հզր
-761,00 հզր
EBT including unusual items
45,45 մլն
-16,86 մլն
-18,87 մլն
-22,49 մլն
EBT excluding unusual items
45,45 մլն
-16,86 մլն
-18,87 մլն
-22,49 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
45,45 մլն
-16,86 մլն
-18,87 մլն
-22,49 մլն
Net profit margin
-
-
-
-
Earnings per share
-
-0,41
-
-0,28
Interest and investment income
655,23 հզր
700,74 հզր
1,05 մլն
1,71 մլն
Interest expense
-43,29 հզր
-63,46 հզր
-62,74 հզր
-62,00 հզր
Net interest expenses
611,94 հզր
637,28 հզր
984,45 հզր
1,65 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-11,91 մլն
-15,01 մլն
-19,25 մլն
-22,54 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps